China’s obesity crisis is a sizeable profit opportunity. More than half of Chinese adults are overweight or obese — a figure expected to hit two-thirds by 2030. That is nearly 900mn people, a market ...

In the latest research, scientists from Canada tracked nearly 3,000 Americans who used either semaglutide, the active drug in ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support ...

People often visit wellness tenants including gyms three to five times a week, he said, which may lead them to patronize ...

Fortunes are being blown on injectable hopes of a slimmer future but a simpler and cheaper alternative could actually be in ...

A DAD-of-five and pub DJ has finally kicked his 20-a-day cigarette habit after 45 years thanks to a pill dubbed ‘Ozempic for ...

Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.

Injectable drugs like Ozempic and Wegovy may be new to most of the world, but the science behind them are familiar to those in the health field.

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...